Oral Cyclosporin vs Infliximab in Patients With Severe Ulcerative Colitis Refractory to Iv Steroids. Preliminary Data of a Controlled, Randomized Study

Bossa, Fabrizio; Caruso, N.; Accadia, L.; Merla, Antonio; Niro, Alfredo; Iacobellis, A.; Colombo, E.; Siena, D.; Ippolito, A.; Andriulli, Angelo; Annese, Vito

doi:10.1016/s1590-8658(09)60007-4

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study (currently published as an abstract only) showed that patients receiving infliximab showed a trend towards greater clinical remission, compared to oral cyclosporine, but experienced more serious opportunistic infections. 31 There is also a suggestion that i.v. cyclosporine treatment may be more appropriate for immunomodulator-naïve patients.…”

Section: Discussionmentioning

confidence: 99%

Infliximab or cyclosporine for acute severe ulcerative colitis: A retrospective analysis

Dean

Hikaka

Huakau

et al. 2012

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Infliximab or cyclosporine for acute severe ulcerative colitis: A retrospective analysis

Dean

Hikaka

Huakau

et al. 2012

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Ninety-seven citations that were not included in the four systematic reviews were assessed for full-text eligibility. Fifteen of them were included, [66][67][68][69][70][71][72][73][74][75][76][77][78][79][80] of which 6 studies included less than 30 patients. [66][67][68][69][70][71] Nine studies that included 706 patients [72][73][74][75][76][77][78][79][80] were added to the 20 studies that included 1490 patients, extracted from the four meta-analyses.…”

Section: Acute Uc In Population-based Studies (Figure 1)mentioning

confidence: 99%

“…Four studies were conference abstracts. 50,51,67,69 The mean age of patients included in population-based studies was 49 ± 5 vs. 37 ± 4 in referral centre-based studies.…”

Section: Acute Uc In Population-based Studies (Figure 1)mentioning

confidence: 99%

Systematic review with meta‐analysis: mortality in acute severe ulcerative colitis

Dong

Metzger

Holsbø

et al. 2019

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Acute severe ulcerative colitis (ASUC) is a life‐threatening condition. Mortality in ASUC decreased in published series but there is uncertainty as to whether this also applies to the real‐life setting. Aim To perform a systematic review and meta‐analysis of mortality in ASUC in studies from referral centres and in population‐based studies, separately and combined. A second aim was to identify risk factors of mortality in ASUC. Methods We searched pubmed and embase from 1998 to 2016, to identify studies that reported 3‐month or 12‐month mortalities of acute UC in adult patients treated in referral centres, and in population‐based studies. Results Six population‐based studies with 741 743 patients and 47 referral centre‐based studies with 2556 patients were included. The pooled 3‐month and 12‐month mortalities were respectively 0.84% and 1.01%. Advanced age was significantly associated with both 3 month and 12 month mortalities (OR = 1.15 per year, 95% CI: 1.10‐1.20 and OR = 1.19 per year, 95% CI: 1.15‐1.23 respectively). The pooled 3‐month and 12‐month mortalities were 0.78% and 0.85% in studies with median age of less than 50 and 2.81% and 4.17% in studies with median age of 50 or more, respectively. After adjustment for age, 3‐month and 12‐month mortalities did not differ between population‐based and referral centre‐based studies. Conclusions Mortality in acute severe ulcerative colitis is approximately 1%; it is higher in older patients. Efforts should be made to improve the care of elderly patients with severe UC.

show abstract

“…A total of 421 patients were included in the analysis for this network meta-analysis. The characteristics and outcomes of the included studies [28][29][30][31][32][33][34][35] are summarized in Tables 1 and S1. Seven studies were conducted among adult subjects, and one study did not mention the age of patients.…”

Section: Resultsmentioning

confidence: 99%

Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta‐analysis

Komaki

Micic

et al. 2017

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

Oral Cyclosporin vs Infliximab in Patients With Severe Ulcerative Colitis Refractory to Iv Steroids. Preliminary Data of a Controlled, Randomized Study

Cited by 4 publications

References 0 publications

Infliximab or cyclosporine for acute severe ulcerative colitis: A retrospective analysis

Infliximab or cyclosporine for acute severe ulcerative colitis: A retrospective analysis

Systematic review with meta‐analysis: mortality in acute severe ulcerative colitis

Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta‐analysis

Contact Info

Product

Resources

About